Global Search

Search articles, concepts, and chapters

Am J OphthalmolSeptember 200724 citations

Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone.

Shukla Dhananjay, Vidhya Nagasubramaniam, Prasad Noela M, Mahalakshmi Rajendran, Kolluru Chandarmohan, Krishnadas Ramaswami


AI Summary

This study found younger patients (≤45) receiving intravitreal triamcinolone experienced more frequent IOP elevation, highlighting the need for age-specific monitoring.

Abstract

Purpose

To evaluate the effect of patient age on intraocular pressure (IOP) response after intravitreal injection of triamcinolone acetonide (IVTA).

Design

Interventional case series.

Methods

A total of 164 outpatients (164 eyes) aged 21 to 80 years (mean, 56.8 years), presenting with exudative age-related maculopathy (51) or macular edema of various etiologies (113), received IVTA (4 mg/0.1 ml). The primary outcome measure was IOP elevation >21 mm Hg. Patients were re-evaluated at one week, and one, three, and six months.

Results

The mean baseline IOP was 15.07 mm Hg; the mean rise was 6.6 mm Hg. IOP >21 mm Hg was observed in 42 (25.6%) patients. In the age group </=45 years, IOP rise occurred in 45% (14/31) patients, compared with 21% (28/133) of older patients (P = .006). The groups were similar in baseline IOP, IOP rise, mean time-lag to maximum IOP, and response to treatment.

Conclusions

IVTA caused more frequent IOP elevation in younger patients; other aspects of IOP response and its treatment were similar to older patients.


MeSH Terms

AdultAge FactorsAgedAged, 80 and overFemaleGlucocorticoidsHumansInjectionsIntraocular PressureMacular DegenerationMacular EdemaMaleMiddle AgedOcular HypertensionProspective StudiesRisk FactorsTriamcinolone AcetonideVitreous Body

Is this article assigned to the wrong chapter(s)? Let us know.